Advertisement
Dr. Itin will present at the 2008 BIO CEO and Investor Conference in NewYork, on Wednesday, February 13, 2008 at 2:00 pm Eastern Time (8:00 pm CentralEuropean Time). An audio webcast of Dr. Itin's remarks will be available liveand accessible through Micromet's website at www.micromet-inc.com, as well asa replay and download of the presentation slides following the event.
Advertisement
Dr. Itin will also present at the Roth Capital Partners 2008 OC GrowthStock Conference in Dana Point California, on Tuesday, February 19, 2008 at9:30 am Pacific Time.
About Micromet, Inc. (www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company developing novel,proprietary antibodies for the treatment of cancer, inflammation andautoimmune diseases. Three of its antibodies are in clinical development.MT103 (MEDI-538), the most advanced antibody in Micromet's product pipelinedeveloped using the BiTE(R) antibody technology platform , is being developedin a phase 2 clinical trial for the treatment of patients with acutelymphoblastic leukemia, and in a phase 1 clinical trial for the treatment ofpatients with non- Hodgkin's lymphoma. BiTE antibodies represent a new classof antibodies that activate a patient's own cytotoxic T cells to eliminatecancer cells. Micromet is developing MT103 in collaboration with MedImmune,Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody isadecatumumab (MT201), a human monoclonal antibody targeting EpCAM expressingsolid tumors. Adecatumumab is being developed by Micromet in collaborationwith Merck Serono in a phase 1b clinical trial evaluating MT201 in combinationwith docetaxel for the treatment of patients with metastatic breast cancer.The third clinical stage antibody is MT293 (TRC093), a first-in-classhumanized monoclonal antibody that inhibits angiogenesis and tumor cell growthby binding cleaved collagen. MT293 is licensed to TRACON Pharmaceuticals, Inc.and is being developed in a phase 1 clinical trial for the treatment ofpatients with cancer and age-related macular degeneration. In addition,Micromet has established a collaboration with Nycomed for the development andcommercialization of MT203, Micromet's human antibody neutralizing theactivity of GM-CSF, which has potential applications in the treatment ofinflammatory diseases, such as rheumatoid arthritis, as well as autoimmunediseases.
SOURCE Micromet, Inc.
